Active substance: Clomiphene
Toledo has a wonderful bedside manner. He is friendly and personable and has been doing this a long time.Just click the link in the at this address. You will then receive an email email, and the verification will be.
It takes a long time to get into see him, but there's a reason for it. You won't be sad you waited an extra few weeks. Some of his explanations are technical, but for the most part, he explains things in terms non-medical people can understand.
He will take as much time as he needs with patients for consultations - I think those are booked in one hour blocks, just so he doesn't have to get to another patient.
I think we spent one hour with him in our initial consult not including exams, bloodwork, and meeting with the nurses before and after. He answers questions patiently and is happy to take follow up calls.
Once we had decided to go forward with IVF, I had questions about the drugs and injections I was prescribed, and I was able to get on the phone with him personally within a couple of days to get answers from him.
These men were defined as the intent-to treat ITT population.
Four men three in the enclomiphene citrate 12. Forty-four subjects completed the study per protocol PP and were defined as the PP population. The mean sd BMI for all men was 34. There was no significant difference in age or BMI among the treatment groups.
Others variables were determined by standard laboratory methods. Analytical procedures to determine concentrations of enclomiphene citrate in human semen were performed at Cetero Research.
Protocol The present study was a randomized, single-blind, phase II, four-arm study with a 6-week active dosing period. The objectives were to assess LH and testosterone levels in men with secondary hypogonadism.
Institutional review board or independent ethics committee approvals were obtained at each centre, all patients provided written informed consent, and the study was conducted in accordance with the Declaration of Helsinki and principles of good clinical practice.
Subjects agreed to use a condom or another form of contraception during the study.
Subjects with diabetes, hyperprolactinaemia, HIV, cataracts, breast or prostate cancer, end-stage renal disease, cystic fibrosis, uncontrolled hypertension, abnormal haemoglobin or heamatocrit, or subjects using medications known to interfere with sex steroid synthesis or action were excluded.
The men in each of the four study arms were randomized to one of three single-blind enclomiphene citrate doses or open label transdermal testosterone.
The doses of enclomiphene citrate in the single-blind portion of the study were enclomiphene citrate 6.